IPO / Stock
Went Public on Jul 10, 2014 / EBR:ARGX
Funding Received
$61.9 Million in 3 Rounds from 11 Investors
Headquarters:
Rotterdam
Description:
arGEN-X has invented and developed a platform for antibody lead choice in the discovery of human antibody therapeutics.
Categories:
Biotechnology
Website:
http://www.argen-x.com

Company Details

Update
Founded:
Unknown
Contact:
Employees:
2 in CrunchBase

To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics.

Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.

Offices/Locations (1)

Update
  • HQ

    Dr Molewaterplein 50

    Rotterdam, 3015

    NLD